Patents Assigned to GTC Biotherapeutics, Inc.
-
Publication number: 20130149301Abstract: The present invention relates to the treatment of inflammatory conditions including atherosclerosis and sepsis. In particular, the invention relates to treatment of these conditions using antibodies.Type: ApplicationFiled: November 29, 2012Publication date: June 13, 2013Applicant: GTC Biotherapeutics, Inc.Inventor: GTC Biotherapeutics, Inc.
-
Publication number: 20120263663Abstract: Methods of preventing photoaging and other types of sun damage by topically applying a composition containing a serine protease inhibitor or milk are provided. Pharmaceutical compositions comprising serine protease inhibitors or milk for the prevention of photoaging and other types of sun damage are also provided.Type: ApplicationFiled: June 22, 2012Publication date: October 18, 2012Applicant: GTC BIOTHERAPEUTICS, INC.Inventors: Eric F. Bernstein, Yann Echelard, Paul Donald Forbes
-
Patent number: 8173860Abstract: The invention provides, in part, methods for the production of proteins in a transgenic non-human mammal, wherein the proteins are transported from the blood to the mammary gland for secretion in milk. The transport of the protein to the mammary gland and/or milk is facilitated by binding to a transport receptor in the mammary gland.Type: GrantFiled: April 20, 2007Date of Patent: May 8, 2012Assignee: GTC Biotherapeutics, Inc.Inventors: Harry M. Meade, Daniel Pollock
-
Publication number: 20120058047Abstract: The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred embodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals. In another preferred embodiment of the current invention the agonistic anti-CD137 antibodies of the invention can be conjugated to radionuclides for radioimmunodetection or radioimmunotherapeutic purposes, or conjugated to a toxin for enhanced therapeutic treatment of various cancers.Type: ApplicationFiled: February 26, 2010Publication date: March 8, 2012Applicants: Mayo Foundation for Medical Education and Research, GTC Biotherapeutics, Inc.Inventors: Scott E. Strome, Daniel Schindler, Lieping Chen, Harry M. Meade, Yann Echelard
-
Publication number: 20110104049Abstract: The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred embodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals. In another preferred embodiment of the current invention the agonistic anti-CD137 antibodies of the invention can be conjugated to radionuclides for radioimmunodetection or radioimmunotherapeutic purposes, or conjugated to a toxin for enhanced therapeutic treatment of various cancers.Type: ApplicationFiled: February 26, 2010Publication date: May 5, 2011Applicants: GTC Biotherapeutics, Inc., Mayo Foundation for Medical Education and ResearchInventors: Scott E. Strome, Daniel Schindler, Lieping Chen, Harry M. Meade, Yann Echelard
-
Patent number: 7928064Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.Type: GrantFiled: November 14, 2005Date of Patent: April 19, 2011Assignee: GTC Biotherapeutics, Inc.Inventors: Paul DiTullio, Harry M. Meade, Edward S. Cole
-
Publication number: 20110082083Abstract: In one aspect, the invention provides liquid stable formulations of antithrombin.Type: ApplicationFiled: May 3, 2010Publication date: April 7, 2011Applicant: GTC Biotherapeutics, Inc.Inventors: Gerald R. Magneson, Greg J. Allard, Nicholas C. Masiello, Usha S. Patel, Lauren K. Fontana, Joseph L. Pearce, Jerry A. Grandoni
-
Publication number: 20100056757Abstract: Processes and apparati are provided for separating molecules of interest from a mixture by depth filtration (DF). The DF of the invention is useful in the clarification and processing of various feedstreams for the removal of a molecule of interest. According to a preferred embodiment, a transgenic milk feedstream is stabilized and particulate matter such as fat, casein miscelles and bacteria are removed. An aseptic filtration step was also developed to remove any bacteria remaining in a clarified transgenic milk feedstream.Type: ApplicationFiled: April 3, 2009Publication date: March 4, 2010Applicant: GTC Biotherapeutics, Inc,Inventor: Mark A. Perreault
-
Publication number: 20100021612Abstract: Desirable fusion proteins can be produced in and purified from the milk of transgenic animals. The peptides are made as fusion proteins with a suitable fusion partner such as human alpha-fetoprotein. The fusion partner protein acts to promote and increase the half-life of the overall molecule as well as having therapeutic effects on its own. The fusion protein is typically produced through the use of transgenic animals and can be purified away from the now the milk or other bodily fluid of such an animal by an affinity purification method. A particular advantage of producing peptides via this route, in addition to the obvious advantages of high yield and biocompatibility, is that specific post-translational modifications, such as carboxy terminal amidation, can be performed in the mammary gland.Type: ApplicationFiled: February 27, 2009Publication date: January 28, 2010Applicant: GTC Biotherapeutics, Inc.Inventors: Harry M. Meade, Geoffrey F. Cox
-
Patent number: 7632980Abstract: The invention provides modified recombinant nucleic acid sequences (preferably DNA) and methods for increasing the mRNA levels and protein expression of proteins which are known to be, or are likely to be, difficult to express in cell culture systems, mammalian cell culture systems, or in transgenic animals. The preferred “difficult” protein candidates for expression using the recombinant techniques of the invention are those proteins derived from heterologous cells preferably those of lower organisms such as parasites, bacteria, and virus, having DNA coding sequences comprising high overall AT content or AT rich regions and/or mRNA instability motifs and/or rare codons relative to the recombinant expression system to be used.Type: GrantFiled: October 20, 1998Date of Patent: December 15, 2009Assignee: GTC Biotherapeutics, Inc.Inventors: Li How Chen, Harry Meade
-
Publication number: 20090246194Abstract: Erythropoietin analog-human IgG fusion protein (EPOa-IgG) fusion protein and methods of making and using the fusion protein.Type: ApplicationFiled: March 18, 2008Publication date: October 1, 2009Applicant: GTC Biotherapeutics, Inc.Inventors: Harry M. Meade, Ian Krane
-
Patent number: 7550263Abstract: Desirable fusion proteins can be produced in and purified from the milk of transgenic animals. The peptides are made as fusion proteins with a suitable fusion partner such as human alpha-fetoprotein. The fusion partner protein acts to promote and increase the half-life of the overall molecule as well as having therapeutic effects on its own. The fusion protein is typically produced through the use of transgenic animals and can be purified away from the now the milk or other bodily fluid of such an animal by an affinity purification method. A particular advantage of producing peptides via this route, in addition to the obvious advantages of high yield and biocompatibility, is that specific post-translational modifications, such as carboxy terminal amidation, can be performed in the mammary gland.Type: GrantFiled: September 3, 2004Date of Patent: June 23, 2009Assignee: GTC Biotherapeutics, Inc.Inventors: Harry Meade, Geoffrey F. Cox
-
Patent number: 7531632Abstract: Processes and apparati are provided for separating molecules of interest from a mixture by depth filtration (DF). The DF of the invention is useful in the clarification and processing of various feedstreams for the removal of a molecule of interest. According to a preferred embodiment, a transgenic milk feedstream is stabilized and particulate matter such as fat, casein miscelles and bacteria are removed. An aseptic filtration step was also developed to remove any bacteria remaining in a clarified transgenic milk feedstream.Type: GrantFiled: February 16, 2006Date of Patent: May 12, 2009Assignee: GTC Biotherapeutics, Inc.Inventor: Mark A. Perreault
-
Patent number: 7501553Abstract: The invention provides modified recombinant nucleic acid sequences (preferably DNA) and methods for increasing the mRNA levels and protein expression of malarial surface protein MSP-1 which is known to be difficult to express in cell culture systems, mammalian cell culture systems, or in transgenic animals. The preferred protein candidates for expression using the recombinant techniques of the invention are MSP-1 proteins expressed from DNA coding sequences comprising reduced overall AT content or AT rich regions and/or mRNA instability motifs and/or rare codons relative to the native MSP-1 gene.Type: GrantFiled: February 20, 2002Date of Patent: March 10, 2009Assignee: GTC Biotherapeutics, Inc.Inventors: Li-How Chen, Harry M. Meade
-
Publication number: 20080118501Abstract: The invention relates, in part, to antibodies with increased ADCC activity. Methods of producing such antibodies are also provided. The antibodies of the invention are produced in mammary epithelial cells, such as those in a non-human transgenic animal engineered to express and secrete the antibody in its milk. The antibodies or compositions comprising the antibodies can be used to treat disease in which ADCC activity provides a benefit. In one embodiment, therefore, the antibodies or compositions comprising the antibodies can be used to treat cancer, lymphoproliferative disease or autoimmune disease.Type: ApplicationFiled: October 23, 2006Publication date: May 22, 2008Applicant: GTC Biotherapeutics, Inc.Inventors: Daniel Schindler, Harry M. Meade, Timothy Edmunds, John McPherson
-
Patent number: 7354594Abstract: The invention provides modified recombinant nucleic acid sequences (preferably DNA) and methods for increasing the mRNA levels and protein expression of malarial surface protein MSP-1 which is known to be difficult to express in cell culture systems, mammalian cell culture systems, or in transgenic animals. The preferred protein candidates for expression using the recombinant techniques of the invention are MSP-1 proteins expressed from DNA coding sequences comprising reduced overall AT content or AT rich regions and/or mRNA instability motifs and/or rare codons relative to the native MSP-1 gene.Type: GrantFiled: May 27, 2005Date of Patent: April 8, 2008Assignee: GTC Biotherapeutics, Inc.Inventors: Li How Chen, Harry M. Meade
-
Publication number: 20080063780Abstract: The invention provides, in part, methods for the production of proteins in a transgenic non-human mammal, wherein the proteins are transported from the blood to the mammary gland for secretion in milk. The transport of the protein to the mammary gland and/or milk is facilitated by binding to a transport receptor in the mammary gland.Type: ApplicationFiled: April 20, 2007Publication date: March 13, 2008Applicant: GTC Biotherapeutics, Inc.Inventors: Harry Meade, Daniel Pollock
-
Patent number: 7271312Abstract: The invention provides modified recombinant nucleic acid sequences (preferably DNA) and methods for increasing the mRNA levels and protein expression of proteins which are known to be, or are likely to be, difficult to express in cell culture systems, mammalian cell culture systems, or in transgenic animals. The preferred “difficult” protein candidates for expression using the recombinant techniques of the invention are those proteins derived from heterologous cells preferably those of lower organisms such as parasites, bacteria, and virus, having DNA coding sequences comprising high overall AT content or AT rich regions and/or mRNA instability motifs and/or rare codons relative to the recombinant expression system to be used.Type: GrantFiled: October 20, 1998Date of Patent: September 18, 2007Assignee: GTC Biotherapeutics, Inc.Inventors: Li How Chen, Harry Meade
-
Publication number: 20070037192Abstract: Methods of purifying antithrombin from a variety of source materials including from the milk of transgenic mammals to enhance its safety profile vis-à-vis the removal and/or the inactivation of contaminants. Contaminants would include particulate matter, viruses, and/or prions.Type: ApplicationFiled: July 25, 2006Publication date: February 15, 2007Applicant: GTC Biotherapeutics, Inc.Inventors: Carol Ziomek, Christopher Hendry
-
Patent number: 7101971Abstract: Erythropoietin analog-human serum albumin (EPOa-hSA) fusion protein and methods of making and using the fusion protein.Type: GrantFiled: February 20, 2002Date of Patent: September 5, 2006Assignee: GTC Biotherapeutics, Inc.Inventors: Harry M. Meade, Ian Krane, Michael Young